ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
1.700 ^USD	0.00%		-13.71%	+50.44%

Mar. 31	Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 31	Certain Options of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI

ALX Oncology : Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186)

Published on 01/15/2026 at 03:20 pm EST

Publicnow

ALX ONCOLOGY HOLDINGS INC.

0.00%

NASDAQ GS

JP Morgan Healthcare Conference January 2026

ALXO

ALX is Rapidly Advancing Novel Cancer Treatments

Leading CD47 program in development with potential to be next targeted immuno-oncology breakthrough
Unique design with inactive Fc differentiated from past attempts to target CD47
Demonstrated activity in five combinations to date and a targetable CD47 biomarker
Advancing trials in breast cancer and multiple myeloma*

Evorpacept

Highly differentiated EGFR ADC now in Ph1 dose escalation in the US
Meticulously designed and developed in-
house to maximize therapeutic window
Preclinical data support dose dependent activity and a differentiated safety profile
Targeting EGFR-expressing tumors in Ph1 including NSCLC, CRC, HNSCC, and ESCC

ALX2004

* Sanofi-sponsored trial

ALX Oncology | J.P. Morgan Healthcare Conference 2026

Strong Execution in 2025 Leads to a Catalyst Rich 2026

✓

ASPEN-06 data at SITC '25: 2L gastric study demonstrated a 65% ORR in treatment vs 26% in control in

HER2+ CD47-high patients; mPFS benefit of 18.4m vs 7.0m (HR 0.3G), mOS 17.0m v G.Gm (HR 0.63)

✓

Jazz collaboration: Evo + zanidatamab demonstrated a 56% ORR in HER2+ breast cancer patients with prior Enhertu

✓

Sanofi collaboration: Evo + Sarclisa + dexamethasone in patients with previously treated multiple myeloma advanced from dose escalation into dose optimization

✓

MDACC NHL data: Evo + R2 demonstrated a 100% ORR, G2% CR rate (historical control is ~50%), and a

1-yr PFS rate of G1% in 1L indolent NHL

✓

ALX2004 enters clinic and rapidly progresses through initial dose levels with no dose-limiting toxicities

ALX Oncology | J.P. Morgan Healthcare Conference 2026

ALX Oncology is Pursuing a Focused Development Plan with Upcoming Catalysts in 2026

M O D A L I T Y

/ T A R G E T P R O G R A M I N D I C A T I O N

E V O R P A C E P T P R O G R A M S

I N D

E N A B L I N G P H A S E 1 P H A S E 2 P H A S E 3 S T A T U S

ASPEN-Breast

Evorpacept, Trastuzumab

+ chemotherapy

ENHERTU®-Experienced HER2-Positive Breast Cancer

Enrolling, interim analysis

anticipated Q3 2026

Anti-cancer Antibodies

SARCLISA® +

Dexamethasone1 + Evorpacept

ASPEN-06

Evorpacept, Trastuzumab, CYRAMZA® + Paclitaxel2

Zanidatamab3 + Evorpacept

RRMM

(Relapsed or Refractory Multiple Myeloma)

2L or 3L Advanced HER2-Overexpressing

Gastric/Gastroesophageal Junction (GEJ)

HER2-Expressing Breast Cancer and Other Cancers

Dose escalation complete, now in dose optimization

Completed,

established POC

Completed,

data presented at

SABCS '24

A L X 2 0 0 4 P R O G R A M

ALX2004

Enrolling,

EGFR ADC

Dose-escalation and expansion

EGFR-Expressing Solid Tumors

Initial safety data 1H

2026

ALX-sponsored trial Completed trial

ALX Oncology retains worldwide rights to evorpacept

1. Sanofi sponsors SARCLISA® clinical trial. 2. Lilly supplies CYRAMZA® for ALX Oncology's ASPEN-06 program 3. Jazz Pharmaceuticals sponsors zanidatamab clinical trial.

5 ALX Oncology | J.P. Morgan Healthcare Conference 2026

EVORPACEPT

Advancing A Synergistic Approach to Cancer Treatment

Evorpacept Blocks the CD47-SIRPα Interaction, Enhancing the Targeted ADCP of Cancer Cells when Given in Combination with Anti-Cancer Antibodies

SIRP Don't

M A C R O P H A G E

Eat Me

SIRP

Don't

M A C R O P H A G E

Eat Me

SIRP

Evorpacept

M A C R O P H A G E

CD47

CD47 CD47

C A N C E R C E L L

Eat Me

FcγR

C A N C E R C E L L

Target antigen

Anti-cancer antibody

Eat Me

FcγR

C A N C E R C E L L

Target antigen

Anti-cancer antibody

Cancer cells overexpress CD47 in order to evade immune detection

ADCP of anti-cancer antibodies is inhibited by CD47

Evorpacept blocks the "don't eat me"

signal and maximizes anti-cancer activity

ALX Oncology | J.P. Morgan Healthcare Conference 2026

Evorpacept Is the Only CD47 Blocker with an Inactive Fc Designed to Avoid Toxicities Seen with Conventional Anti-CD47

Conventional anti-CD47 with active Fc

Evorpacept with inactive Fc

SIRP

M A C R O P H A G E

Eat me

R e d B l o o d C e l l

CD47

Conventional Anti-CD47

Due to CD47's expression on red blood cells, this caused on-target, off-tumor toxicities Inactive Fc spares normal cells minimizing toxicity

8 ALX Oncology | J.P. Morgan Healthcare Conference 2026

Evorpacept's MOA with Anti-Cancer Antibodies has Demonstrated Consistent

evorpacept

Herceptin

evorpacept

Herceptin

evorpacept

Zanidatamab

evorpacept

Rituxan

Positive randomized Positive ph1b in

Ph2 in gastric cancer

gastric cancer

Positive ph1b in breast cancer

Positive ph1b in 1L/ 2L NHL

Tolerability and Robust Clinical Activity vs. Conventional Approaches

Evorpacept

Inactive Fc domain

Evo is the only Fc-inactive clinical-stage program and has shown consistent activity and tolerability

Lemzo-

parlimab

TTI-622

TTI-621

Magrolimab

Hematologic Hematologic toxicity signal toxicity signal

Hematologic toxicity signal

Active Fc domain

Conventional CD47 Blockers

Clinical trials of Fc-active programs have been mostly discontinued/ deprioritized

ALX Oncology | J.P. Morgan Healthcare Conference 2026

EVORPACEPT

Clinical data with anti-cancer antibodies

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

ALX Oncology Holdings Inc. published this content on January 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 15, 2026 at 20:19 UTC.

Latest news about ALX Oncology Holdings Inc.

Mar. 31	Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 31	Certain Options of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 31	Certain Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 31	Certain Performance Based Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 31	Certain Warrants of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.	CI
Mar. 19	Wells Fargo Initiates ALX Oncology at Overweight With $5 Price Target	MT
Feb. 27	ALX Oncology Holdings Inc., Q4 2025 Earnings Call, Feb 27, 2026
Feb. 27	ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 15	ALX Oncology Holdings Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 12:00 PM
Jan. 08	ALX Oncology Holdings Inc. Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004	CI
Dec. 07	Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymphoma	CI
Nov. 07	ALX Oncology Holdings Inc., Q3 2025 Earnings Call, Nov 07, 2025
Nov. 07	ALX Oncology Q3 net loss narrows as R&D costs drop	RE
Nov. 07	ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Chart ALX Oncology Holdings Inc.

Duration

Period

ALXO: Dynamic Chart

Company Profile

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a donâ€™t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company